The United States Department of Defense (DOD) awarded Moderna a contract valued at $1,966,598,000 for an additional 100 million doses of the company’s Covid-19 vaccine.
Myovant Sciences’ stock rocketed on news that the company was partnering with Pfizer to develop and commercialize Orgovyx (relugolix) for prostate cancer and women’s health.
Dr. Reddy’s Canada filed an application for Reeqonus (favipiravir) Tablets for the acute treatment of mild-to-moderate Covid-19 adult patients under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to Covid-19.
Countries across the globe shut their borders to Britain on Dec. 21 due to fears about a highly infectious new coronavirus strain, causing travel chaos and raising the prospect of food shortages days before Britain is set to leave the European Union.
Europe’s health regulator started a real-time review of Johnson & Johnson’s Covid-19 vaccine candidate after preliminary results showed that the shot triggered the production of antibodies and immune cells against the virus.
COVID-19 cases still surging in the Americas, the WHO warns BRASILIA (Reuters) – COVID-19 cases are still surging in the Americas, averaging 150,000 a day in last week, the World […]
Will the solitary path the United States is on, insulate it from further Covid-19 pandemic-related damage? Christopher Snyder, a professor of economics at Dartmouth University, believes the answer depends largely on the eventual vaccine’s level of efficacy.
Treating critically ill Covid-19 patients with corticosteroid drugs reduces the risk of death by 20 percent, an analysis of seven international trials found, prompting the World Health Organization to update its advice on treatment.
A study of Fitbit wearers concludes that almost 50 percent of Covid-19 cases can be detected a day before enrollees in the study reported the onset of symptoms, and with 70 percent specificity.
The United States entered an agreement with drugmaker Moderna Inc. to acquire 100 million doses of the company’s potential COVID-19 vaccine for around $1.5 billion, the company and White House said.
